Premium
Chromosome aberrations of human small cell lung cancer induced by a new 111 in‐bleomycin complex
Author(s) -
Hou DeYan,
Maruyama Yosh,
Drago Joseph R.
Publication year - 1992
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930510407
Subject(s) - bleomycin , colcemid , cancer research , lung cancer , chromosome , medicine , cancer cell , cancer , radiation therapy , pathology , cell , microbiology and biotechnology , biology , chemotherapy , genetics , gene
A new 111 Indium labeled bleomycin complex ( 111 In‐BLMC) was prepared and found to be effective for tumor imaging and therapy both in mouse glioma and human small cell lung cancer (SCLC) cells. Chromosome aberrations were studied in human SCLC cells to explore its mechanisms of killing cancer cells. SCLC cells (N417) were exposed to 111 In‐BLMC, BLM, or 111 InCl 3 (for control) for 1 hour, treated with colcemid, and chromosomal changes were analyzed. A dramatic increase in chromatic gaps, breaks, chromosome breaks, double minutes, rings, triradii, quadriradii, and chromosome stickiness were observed in the cells treated by 111 In‐BLMC compared to BLM or 111 InCl 3 . These results indicated that 111 In‐BLMC has therapeutic potential for combination chemo‐radiotherapy of cancer (e.g., by Auger electrons and local energy deposition). © 1992 Wiley‐Liss, Inc.